BlueJay Therapeutics

BlueJay Therapeutics

  • Founded: 2019
  • Location: San Francisco, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1b
  • Therapy area: Hepatitis B
  • Drug types: INF
  • Lead product: BJT-778
  • Product link:
  • Funding: $41M B Aug 2022
  • Investors: Arkin Bio Ventures, Synergenics LLC, RiverVest Venture Partners, Yonjin Capital, Octagon Capital, InnoPinnacle International

job board

Short description:

Monoclonal Antibody, Small Molecule

Drug notes:

Also Clin1 hepatitis D; BJT-628 Clin0 hepatitis B

Long description:

BlueJay Therapeutics is developing therapeutics for the treatment of infectious diseases. In 2019, 296M people worldwide were living with hepatitis B. With decades of experience in HBV, virology, immunology and liver diseases, BlueJay is identifying and developing highly differentiated assets that offer the greatest therapeutic potential with the lowest risk for patients. BlueJay’s assets currently consist of antibody biologics and small molecules. BlueJay’s lead candidate, BJT-778, a best-in-class monoclonal antibody against hepatitis B surface antigen, recently received regulatory clearance to initiate clinical studies for patients with chronic hepatitis B. BJT-778 may help to reconstitute a patient’s antiviral immunity by neutralizing and clearing hepatitis B virions.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy